NCT07004192 The Role of hCG in Thawed Embryo Transfer
| NCT ID | NCT07004192 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Fertility Center of Las Vegas |
| Condition | Infertility (IVF Patients) |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2025-06-02 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 220 participants in total. It began in 2025-06-02 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hCG in transfers of thawed embryos.
Eligibility Criteria
Inclusion Criteria: 1. Female adult expecting to receive transfer of a thawed embryo. 2. At least one available frozen blastocyst of transferrable quality. 3. Non-menopausal female with at least one antral follicle. 4. Use of pre-implantation genetic testing (PGT), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed. 5. Subsequent embryo transfers after failed transfers under this study are allowed, but not after a transfer that has resulted in ongoing pregnancy at ten weeks gestation under this study. Exclusion Criteria: 1. Minors (age\<18 years). 2. Use of embryo(s) frozen at another center. 3. Patient insistent on transfer of two embryos. 4. Patient or partner unable to provide informed consent in English. 5. Patient already enrolled in any other research study for her embryo transfer. 6. History of anti-phospholipid syndrome or any other indication for use of Lovenox in pregnancy. 7. Patient for whom the physician assesses this protocol is inappropriate or unsafe.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07004192 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Infertility (IVF Patients). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07004192 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07004192 currently recruiting?
Yes, NCT07004192 is actively recruiting participants. Contact the research team at shironda@fertilitycenterlv.com for enrollment information.
Where is the NCT07004192 trial being conducted?
This trial is being conducted at Las Vegas, United States.
Who is sponsoring the NCT07004192 clinical trial?
NCT07004192 is sponsored by Fertility Center of Las Vegas. The trial plans to enroll 220 participants.